Pain medicine

CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial

JAMA Netw OpenPublished Randomised controlled trial

Primary resultResult — go to the resultDifference 2.8 95% CI −18.3 to 23.8

Authors' conclusion

In this randomized clinical trial of CYP2D6-guided postoperative opioid prescribing, there were significant prescribing changes in CYP2D6 poor and intermediate metabolizers but no differences in pain control compared with usual care.

Study context

Population
CYP2D6 poor or intermediate metabolizers undergoing planned surgery anticipated to cause postoperative pain for at least 7 to 10 days, 8 US health systems1,602 enrolled
Participants
351 participants
Comparison
CYP2D6-guided opioid prescribing vs usual pain management
  • CYP2D6-guidedn = 176
  • Controln = 175reference
Primary endpoint
Silverman integrated analgesic assessment (SIA) score (rank-based composite of average pain intensity and opioid use in MME)
Follow-up
10 days
Methodological detailsopen-label, multicentre
  • Open-label
  • Multicentre

Primary result

As reported in the abstract

Difference

2.8

95% CI −18.3 to 23.8

P = 0.80

By group

CYP2D6-guided

1.4

mean · SD 95.9

Control

−1.4

mean · SD 93.1

CYP2D6-guided vs Control
difference 2.8 (95% CI −18.3 to 23.8); P = 0.80

Secondary outcomes

OutcomeCYP2D6-guidedControlDifference (percentage points) (95% CI)P value
Concordance between postsurgical opioid treatment and CYP2D6 phenotype64%27%37 (27–46)P < 0.001

Overall opioid use

Mean

OutcomeCYP2D6-guidedControl
Numeric pain intensity rating5.2 (SD 2.2)5.1 (SD 2.3)

Numeric pain intensity rating

Did not differ between arms

Overall opioid use

Did not differ between arms; other secondary end points also did not differ

Original publication

CYP2D6-Guided Opioid Management and Postoperative Pain Control: A Randomized Clinical Trial. JAMA Netw Open. Published 2 February 2026. doi:10.1001/jamanetworkopen.2025.58299

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.